Parameter | Treatment 1 | Treatment 2 | Treatment 3 | Treatment 4 |
---|
Cmax (ng/mL) | 111 [45.2–183] | 96.7 [52.1–169] | 244 [133–479] | 144 [58–200] |
Tmax (h) | 1.41 [0.762–2.06] | 1.09 [0.773–2.28] | 1.72 [1.12–3.65] | 0.992 [0.628–1.90] |
t1/2 (h) | 1.97 [1.64–3.37] | 1.80 [1.46–3.20] | 1.93 [1.71–2.43] | 2.02 [1.64–2.42] |
AUC0–12 (ng × h/mL) | 461 [144–651] | 342 [178–624] | 956 [462–1973] | 462 [189–744] |
AUC∞ (ng × h/mL) | 441 [472–146] | 349 [181–642] | 994 [468–2040] | 467 [192–761] |
- Secondary parameters estimated from the final model and values are presented as median [range]. C
max
is the maximum concentration and T
max
is the time to reach Cmax. t
1/2
is the estimated terminal elimination half-life. AUC
0–12
is the accumulated area under the concentration–time curve from time zero to 12 h after dose and AUC
∞
is the accumulated area under the concentration–time curve from time zero extrapolated to infinity. Treatment 1 was administrated as 160 mg micronized artemisinin, treatment 2 was 160 mg of the reference formulation of artemisinin, treatment 3 was 500 mg of the reference formulation of artemisinin and treatment 4 was 160 mg micronized artemisinin and 720 mg of piperaquine phosphate